INDIA – Aryastha Life Sciences, a Hyderabad, India-based healthcare contract research and development organization, raised an undisclosed amount in Series A funding.
Vessella Group made a significant investment.The company intends to use the funds to accelerate drug discovery and development in the pharmaceutical and biotech sectors.Led by CEO Raghava Reddy Kethiri, and Chief Scientific Advisor, Dr. Pradip K. Majumder, Ph.D., Aryastha is a Life Science service provider that offers CRDMO solutions for novel drug development. The company uses AI, advanced preclinical models derived from patient samples and pluripotent stem cells for efficient drug screening. This approach accelerates the clinical translatability of candidates, streamlining services across the value chain and addressing pharmaceutical industry challenges. 29/08/2023
